Jaguar Health Risks Nasdaq Delisting Over Low Stock Price
Company Announcements

Jaguar Health Risks Nasdaq Delisting Over Low Stock Price

Jaguar Animal Health (JAGX) has released an update.

Jaguar Health, Inc. is on the brink of being delisted from the Nasdaq as its stock price has failed to meet the minimum $1.00 requirement for an extended period. Despite receiving grace periods to rectify the issue, the company’s stock has continued to plummet, currently trading at $0.10 or less. The company faces delisting effective February 26, 2024, but has the chance to appeal before then. Amidst this precarious situation, Jaguar Health is considering all available options to regain compliance and maintain its listing, but there is no guarantee of success.

For further insights into JAGX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyJaguar Health celebrates National Service Dog Month
TheFlyJaguar Health announces patent issued in Jordan for SBS treatment
TheFlyJaguar Health’s Napo Pharmaceuticals issues Hong Kong patent for SBS treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App